Drug Trial Radar · NCT05221008
A Trial of SHR6508 in Secondary Hyperparathyroidism
Last checked: Nov 19, 2026Latest source record: Aug 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Mar 10, 2022
Primary completion
Jul 7, 2023
Study completion Aug 2, 2023
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the tolerability, pharmacokinetics and pharmacodynamics of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis
Conditions
- Secondary Hyperparathyroidism
Interventions
SHR6508;PlaceboDrug
Group A:SHR6508 low dose
SHR6508;PlaceboDrug
Group B:SHR6508 medium dose
SHR6508;PlaceboDrug
Group C:SHR6508 high dose
SHR6508;PlaceboDrug
Group D:SHR6508 high dose(single dose)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tmax, Time of maximum observed concentration.Time frame: 0 hour to 43 hours after first dose administration
- Cmax, Maximum observed concentration.Time frame: 0 hour to 43 hours after first dose administration
- AUC0-t, Area under the concentration-time curve from time zero to the last measurable concentration.Time frame: 0 hour to 43 hours after first dose administration
- AUC0-∞, Area under the curve from time 0 extrapolated to infinite timeTime frame: 0 hour to 43 hours after first dose administration
- t1/2z, Terminal elimination half-lifeTime frame: 0 hour to 43 hours after first dose administration
- CLz, Total Body ClearanceTime frame: 0 hour to 43 hours after first dose administration
- Vz, Volume of distribution based on the terminal phaseTime frame: 0 hour to 43 hours after first dose administration
- MRT0-t, Mean residence time from time zero to the last measurable concentration.Time frame: 0 hour to 43 hours after first dose administration
- MRT0-∞, Mean residence time from time 0 extrapolated to infinite timeTime frame: 0 hour to 43 hours after first dose administration
- Cmax,ss : Maximum observed concentration at steady-state.Time frame: Day1-Day29(if reach steady-state)
- Cmin,ss : Minimum observed concentration at steady-stateTime frame: Day1-Day29(if reach steady-state)
- Cav : Average concentrationTime frame: Day1-Day29(if reach steady-state)
- AUC0-t,ss, Area under the concentration-time curve from time zero to the last measurable concentration at steady-state.Time frame: Day1-Day29(if reach steady-state)
- AUC0-∞,ss, Area under the concentration-time curve from time 0 extrapolated to infinite time at steady-state.Time frame: Day1-Day29(if reach steady-state)
- Tmax,ss, Time of maximum observed concentration at steady-state.Time frame: Day1-Day29(if reach steady-state)
- t1/2z,ss, Terminal elimination half-life at steady-stateTime frame: Day1-Day29(if reach steady-state)
- CLss, Total Body Clearance at steady-state.Time frame: Day1-Day29(if reach steady-state)
- Vss, Volume of distribution based on the terminal phase at steady-state.Time frame: Day1-Day29(if reach steady-state)
- MRT0-∞, Mean residence time from time 0 extrapolated to infinite time.Time frame: Day1-Day29(if reach steady-state)
- DF: Degree of FluctuationTime frame: Day1-Day29(if reach steady-state)
- Accumulation RatioTime frame: Day1-Day29(if reach steady-state)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.